Trifecta-Kidney cfDNA-MMDx Study

Description

Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood, and the Molecular Microscope® (MMDx) Diagnostic System results in indication biopsies.

Conditions

Kidney Transplant Rejection

Study Overview

Study Details

Study overview

Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood, and the Molecular Microscope® (MMDx) Diagnostic System results in indication biopsies.

Trifecta-Kidney cfDNA-MMDx Study: Comparing the DD-cfDNA Test to MMDx Microarray Test, Central HLA Antibody Test, and Histology.

Trifecta-Kidney cfDNA-MMDx Study

Condition
Kidney Transplant Rejection
Intervention / Treatment

-

Contacts and Locations

Tampa

Tampa General Hospital, Tampa, Florida, United States, 33606

Baltimore

University of Maryland School of Medicine, Baltimore, Maryland, United States, 21201

Baltimore

The Johns Hopkins University, School of Medicine, Baltimore, Maryland, United States, 21205

Detroit

Detroit Medical Center, Harper University Hospital of Wayne State University, Detroit, Michigan, United States, 48201

Detroit

Henry Ford Hospital, Detroit, Michigan, United States, 48202

Saint Louis

Barnes-Jewish Hospital, Washington University at St. Louis, Saint Louis, Missouri, United States, 63110

Cleveland

University Hospitals Cleveland Medical Ctr., Cleveland, Ohio, United States, 44106-5048

Cleveland

Cleveland Clinic, Cleveland, Ohio, United States, 44195

Murray

Intermountain Transplant Services, Murray, Utah, United States, 84107

Richmond

Virginia Commonwealth University Medical Center, Richmond, Virginia, United States, 23298

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * All kidney transplant recipients undergoing a kidney biopsy for clinical indications, as determined by their physician or surgeon, will be eligible to enroll in the study.
  • * Patients will be excluded from the study if they decline participation or are unable to give informed consent or multiple organ recipients.

Ages Eligible for Study

to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Alberta,

Philip F Halloran, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Alberta

Study Record Dates

2026-12